Abata Therapeutics

VP, Strategic Sourcing & Procurement

Remote

Not SpecifiedCompensation
Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
BiotechnologyIndustries

Requirements

The VP, Strategic Sourcing & Procurement will lead Apogee’s strategic sourcing and procurement efforts, reporting to the SVP of Finance. This role requires establishing and building a critical function as the company grows, with a focus on building long-term vendor relationships to drive value and support the company’s mission. Strong analytical skills and experience in spend analysis are also needed to identify cost-saving opportunities and ensure compliance with company policies and regulations.

Responsibilities

This position involves developing a sourcing strategy, engaging with potential vendors, selecting partners, and managing the RFP/RFQ/RFI process in collaboration with business stakeholders and legal. The VP will also develop procurement strategies, manage the preferred vendor list, conduct spend analysis, build and maintain supplier relationships, negotiate contracts, oversee procurement operations, monitor performance, and ensure compliance with relevant laws, regulations, and company policies. Additionally, they will act as a strategic partner with functional business partners across the company, particularly in clinical development, clinical operations, and manufacturing.

Skills

Strategic Sourcing
Procurement
Vendor Relationship Management
Biotech Industry Knowledge
Supply Chain Strategy
Stakeholder Collaboration

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Key Metrics

Cambridge, MassachusettsHeadquarters
2021Year Founded
$184.8MTotal Funding
EARLY_VCCompany Stage
BiotechnologyIndustries
11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.
Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.
Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.
Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.
Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.
FDA's accelerated approval pathways may expedite Abata's clinical trials.
Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI